Constitutively high levels of MYC expression can result from translocations that juxtapose the MYC gene locus with other enhancer regions such as the immunoglobulin (Ig) heavy chain enhancer as in Burkitt lymphoma, or through complex chromosomal rearrangements as in the case of multiple myeloma [131, 132]. The gene discussed is MYC; the disease is plasma cell myeloma.